Actavis announced that it has received approval from the FDA to market Methylphenidate HCl extended-release capsules, the generic version of Ritalin LA (Novartis). Actavis will have 180-day first-to-file exclusivity rights on the 20mg, 30mg, and 40mg dosage strengths.

Methylphenidate HCl extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

For more information, call (973) 993-4500 or visit www.actavis.us.